Advanced Statistical Methods for Translational Research

Slides:



Advertisements
Similar presentations
Interim Analysis in Clinical Trials: A Bayesian Approach in the Regulatory Setting Telba Z. Irony, Ph.D. and Gene Pennello, Ph.D. Division of Biostatistics.
Advertisements

The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
Industry Issues: Dataset Preparation for Time to Event Analysis Davis Gates Schering Plough Research Institute.
Agency for Healthcare Research and Quality (AHRQ)
Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Study Objectives and Questions for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Designing Clinical Research Studies An overview S.F. O’Brien.
Adjusting to Life Chapter 1: Human Adjustment John W. Santrock McGraw-Hill © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Chapter 9 Hypothesis Testing Understandable Statistics Ninth Edition
Bayesian posterior predictive probability - what do interim analyses mean for decision making? Oscar Della Pasqua & Gijs Santen Clinical Pharmacology Modelling.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 12 Measures of Association.
Departments of Medicine and Biostatistics
Chapter 1 Conducting & Reading Research Baumgartner et al Chapter 1 Nature and Purpose of Research.
Sample Size Determination Ziad Taib March 7, 2014.
Inferential Statistics
Educational Research Chapter 13 Post-Analysis Considerations Gay, Mills, and Airasian.
Audit Evidence Advanced Auditing Lecture 3 Dr. Mohamed A. Hamada.
AM Recitation 2/10/11.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 7: Gathering Evidence for Practice.
Advanced Statistics for Researchers Meta-analysis and Systematic Review Avoiding bias in literature review and calculating effect sizes Dr. Chris Rakes.
CHAPTER 16: Inference in Practice. Chapter 16 Concepts 2  Conditions for Inference in Practice  Cautions About Confidence Intervals  Cautions About.
Empowering Evidence: Basic Statistics June 3, 2015 Julian Wolfson, Ph.D. Division of Biostatistics School of Public Health.
Some ACS Data Issues and Statistical Significance (MOEs) Table Release Rules Statistical Filtering & Collapsing Disclosure Review Board Statistical Significance.
The Choice Between Fixed and Random Effects Models: Some Considerations For Educational Research Clarke, Crawford, Steele and Vignoles and funding from.
Lecture 16 Section 8.1 Objectives: Testing Statistical Hypotheses − Stating hypotheses statements − Type I and II errors − Conducting a hypothesis test.
Economics 173 Business Statistics Lecture 4 Fall, 2001 Professor J. Petry
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Hypothesis Testing An understanding of the method of hypothesis testing is essential for understanding how both the natural and social sciences advance.
Chapter 10 Copyright © Allyn & Bacon 2008 This multimedia product and its contents are protected under copyright law. The following are prohibited by law:
IMPORTANCE OF STATISTICS MR.CHITHRAVEL.V ASST.PROFESSOR ACN.
Statistical inference Statistical inference Its application for health science research Bandit Thinkhamrop, Ph.D.(Statistics) Department of Biostatistics.
The Role of Statistics and Statisticians in Effectiveness Evaluations Wendy Bergerud Research Branch BC Min. of Forests November 2002.
Research Design
Leveraging Bayesian Methodology to Increase the Trial Efficiency
Logic of Hypothesis Testing
INTRODUCTION AND DEFINITIONS
Sample Size Determination
What’s Beyond Poolability: Exchangability
FDA Division of Cardiovascular Devices
The Importance of Adequately Powered Studies
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Use of Prior Information (Clinical, Pre-clinical and Models) to Improve Efficiency and the Efficacy Estimates Roseann M. White, MA Director of Clinical.
Tests of Significance The reasoning of significance tests
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
CHAPTER 9 Testing a Claim
Clinical and Fiscal “Cost of Delay” – a statistician’s view
FAVOR II Europe-Japan FAVOR II E-J
Clinical Study Results Publication
Sampling And Sampling Methods.
[ March 9, 2017] [ Bill Bowles, Audit Supervisor]
Critical Reading of Clinical Study Results
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Crucial Statistical Caveats for Percutaneous Valve Trials
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Aiying Chen, Scott Patterson, Fabrice Bailleux and Ehab Bassily
Significance and t testing
CHAPTER 18: Inference in Practice
Tim Auton, Astellas September 2014
Why use marginal model when I can use a multi-level model?
By the completion of this presentation, the participant will be able to:
Introduction to Hypothesis Testing
Thinking critically with psychological science
Understanding Statistical Inferences
Two Halves to Statistics
CHAPTER 16: Inference in Practice
Introduction to the design (and analysis) of experiments
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Effect
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
David Manner JSM Presentation July 29, 2019
Assessing Similarity to Support Pediatric Extrapolation
Presentation transcript:

Advanced Statistical Methods for Translational Research Context, Process, Purpose

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company My employer provides testing and consulting services to medical device companies Multiple All TCT 2018 faculty disclosures are listed online and on the App.

We are driven to make a scientific contribution to every medical device in the world

Why do we need “advanced” statistical methods? Better answers Faster answers Cheaper answers

Dangers of “advanced” statistical methods? Wrong answers Delayed answers Expensive answers

Dangers of “advanced” statistical methods? Wrong answers Delayed answers Expensive answers “Being a statistician is like being in Alcoholics Anonymous. You try as hard as you can to not fool yourself” Paraphrasing Jim Hodges

Examples of advanced methods Multiple imputation for missing data Propensity score adjustment for non-randomized comparisons Finkelstein-Schoenfeld / “Win-ratio” for composite endpoints Hiearchical models Bayesian approaches: sample size re-estimation, using historical data

How do we evaluate a new statistical method? Does the novel method address a practical problem? What problems does a novel method raise? Role of pre-specification Operating characteristics Urgency of public health need 𝑞(𝜃| 𝐷 0 , 𝐷, 𝛼 0 )∝ 𝐿(𝜃|𝐷)𝐿(𝜃| 𝐷 0 ) 𝛼 0 𝜋 0 (𝜃)

Does the method address a practical problem? If not, why not use a traditional / non-advanced method? How serious is the practical problem? How well does the method address it?

What problems does a novel method raise? Are the assumptions of the method reasonable at the design stage? Are they met for the data we obtained? How thoroughly has the new method been evaluated? Has it been evaluated for the specific circumstances at hand?

Role of pre-specification When we see a new method applied, was it pre-specified? If not, consider the use of the method an exploratory case-study If it was pre-specified, was the study design aligned? Sample size calculations should be based on the planned analysis method Crossover studies, longitudinal studies, etc., require special methods

Operating characteristics Higher power (low type II error rate) Low chance of false-positive (low type I error rate) Under what conditions is the new method optimal/non-optimal?

Urgent public health need Sometimes we need faster answers HIV/AIDS crisis, Ebola vaccine, opioid crisis Device improvements to solve urgent device-related problems Need for high power is the driving consideration What tradeoffs of other considerations can be made? Considerations not purely statistical, e.g. shorter term endpoints

Context, Process, and Purpose P-values… “Scientific conclusions and business or policy decisions should not be based only on whether a p-value passes a specific threshold” From: The American Statistical Association Statement on P-values Context, Process, and Purpose

A mock example We have a study with P<0.05!!! Based on a small study Clinically meaningful effect size Analysis based on KM analysis KM stands for Kushner-Manafort test Just kidding – it’s Kaplan-Meier/log-rank test, but the test was not pre-specified

A more realistic example: Kaplan-Meier analysis was once new Addressed practical problems Better handling of time to event data Better handling of censored data (losses-to-follow-up) New problems? Difficulty interpreting? This improved with usage Glosses over issue of informative censoring

Another example: Evaluating methods for “borrowing data” Bayesian methods can be used to “borrow” strength from prior work Formalizes incorporation of existing knowledge Posterior = current data x prior data How much strength should we borrow?

Hierarchical Models

Hierarchical Models Reasonable operating characteristics Only applicable when we have a hierarchical structure Somewhat challenging to describe how much we’re “borrowing”

Prior counts as much as current data Bayesian power prior Traditional Bayesian inference: Nfinal = Ncurrent + Nprior Power prior inference Nfinal = Ncurrent + a*Nprior Prior counts as much as current data

For a <1, prior has less weight Bayesian power prior Traditional Bayesian inference: Nfinal = Ncurrent + Nprior Power prior inference Nfinal = Ncurrent + a*Nprior For a <1, prior has less weight

How should we weight historical data? Historical and current data similar (Easy case) Historical and current data different Weight equally? Ignore prior? Posterior Historical data Current data

Can the weight be dynamic? adaptive? Allow weight to vary as a function of agreement? More agreement = more weight Less agreement = less weight

Advantages of dynamic prior Better type I error rate Less bias

When should we prefer fixed vs. dynamic borrowing? While both approaches rely on theory and data… Fixed borrowing can be considered theory driven We believe a priori that historical and current data should be similar Dynamic borrowing can be considered data driven We allow that historical and current data may or may not be similar

When should we prefer fixed vs. dynamic borrowing? Prefer Theory Driven Prefer Data Driven Reason to believe historical data is representative Questionable if historical data Is representative Identical device, patient population, protocol Small differences in device, patient population, or protocol

Criticisms of dynamic borrowing and responses Data are “used twice”; could introduce bias Shows less bias than other methods of borrowing Other statistical methods use data “twice” (e.g. propensity scores, multiple imputation, interim analyses) Amount of borrowing should depend on study design and clinical considerations Use pre-specification Set specifics of model based on these considerations Lack of straightforward clinical interpretation Criticism also applies to other borrowing methods Common tradeoff with adaptive methods Dynamic borrowing is data driven borrowing http://mdic.org/cts/vp/ MDIC Workshop on Virtual Patient Methodology

For advanced statistical methods, consider… Not just the p-value but the Context, Process, and Purpose

Thank you!